estones ahead of
schedule including initiation of the Phase II breast cancer trial and
accelerated enrollment of patients into the Phase II melanoma trial,"
commented Dr. Tim Shannon, President and Chief Executive Officer of
CuraGen. "Over the remainder of 2008, we look forward to completing
enrollment in the melanoma study and subsequently presenting updated
results during the fourth quarter of this year."
CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage
biopharmaceutical company developing diverse approaches for the treatment
of cancer. CuraGen Corporation is headquartered in Branford, Connecticut.
For additional information please visit http://www.curagen.com.
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or prospects,
including statements relating to the Company's revenue, expenses,
depreciation, amortization, asset impairment charges, losses, income, and
future cash and investment positions, including for the second half of 2008
and fiscal year 2008, the timing and expected results of our clinical
programs, and the development and marketability of planned drugs, may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements can be
identified by terminology such as "anticipate," "believe," "could," "could
increase the likelihood," "estimate," "expect," "intend," "is planned,"
"may," "should," "will," "will enable," "would be expected," "look
forward," "may provide," "would" or similar terms, variations of such terms
or the negative of those terms. SuchPage: 1 2 3 4 5 Related medicine technology :1
. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs2
. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia3
. CuraGen Announces Top-Line Phase II Results on Velafermin4
. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma5
. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference6
. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting7
. CuraGen Advances CR011-vcMMAE into Phase II8
. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma9
. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma10
. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer11
. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound